![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
No Meaningful Pharmacokinetic Interaction Between Hepatitis C Virus Protease Inhibitor MK-5172 and Ethinyl Estradiol and Levonorgestrel
|
|
|
Reported by Jules Levin
Presented at HEPDART 2013: Frontiers in Drug Development for Viral Hepatitis, December 8-12, 2013, Big Island, Hawaii
WW Yeh1, CB Smith1, L Caro1, J Talaty1, Z Guo1, TE O'Reilly2, and JR Butterton1
1Merck & Co., Inc., Whitehouse Station NJ, USA, 2Celerion, Phoenix, AZ, USA
![AASLD1.gif](../images/121613/121613-3/AASLD1.gif)
![AASLD2.gif](../images/121613/121613-3/AASLD2.gif)
![AASLD3.gif](../images/121613/121613-3/AASLD3.gif)
![AASLD4.gif](../images/121613/121613-3/AASLD4.gif)
![AASLD5.gif](../images/121613/121613-3/AASLD5.gif)
![AASLD6.gif](../images/121613/121613-3/AASLD6.gif)
![AASLD7.gif](../images/121613/121613-3/AASLD7.gif)
![AASLD8.gif](../images/121613/121613-3/AASLD8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|